Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Atlanta Braves Holdings, Inc.
Current$50.56
Nov 7, 2026

Atlanta Braves owns a scarce MLB franchise and valuable surrounding real estate with long-term appreciation potential, but weak profitability, negative cash flow, and a premium valuation limit its current investment appeal.

Score
43
Avis Budget Group, Inc.
CAR·Industrials
F Avoid
Current$120.44
Nov 6, 2026

Avis Budget could benefit from improving fleet utilization, lower vehicle costs, and debt reduction, but elevated leverage, weak capital returns, and cyclical rental demand create substantial downside risk.

Score
43
DICK'S Sporting Goods, Inc.
Current$127.35
Aug 30, 2026

The core DICK'S banner remains a highly profitable retail machine, but the dilutive Foot Locker acquisition has hurt the consolidated margin profile, exposing investors to turnaround risk and further earnings pressure in a promotional market.

Score
43
Oruka Therapeutics, Inc.
ORKA·Healthcare
F Avoid
Current$107.17
Nov 12, 2026

Oruka's long-acting immunology antibodies show promising clinical efficacy and durability with substantial funding, but a demanding precommercial valuation, major dilution, and unresolved Phase 3 risks weaken its investment appeal.

Score
42
Tango Therapeutics, Inc.
TNGX·Healthcare
F Avoid
Current$25.73
Nov 12, 2026

Tango Therapeutics has promising PRMT5-targeted oncology programs and substantial liquidity, but its valuation depends on unproven pivotal outcomes while persistent losses and significant shareholder dilution threaten per-share value.

Score
42
NexGen Energy Ltd.
NXE·Energy
F Avoid
Current$8.32
Nov 12, 2026

NexGen Energy controls a potentially world-class, low-cost Canadian uranium project with strong long-term nuclear fuel demand exposure, but major construction funding needs, dilution risk, and years without production weaken its current investment appeal.

Score
42
Cogent Biosciences, Inc.
COGT·Healthcare
F Avoid
Current$32.97
Nov 10, 2026

Cogent Biosciences has three potentially transformative FDA decisions backed by strong pivotal clinical data, but its unproven commercial economics, substantial dilution, and demanding valuation create significant investment risk.

Score
42
Celcuity Inc.
CELC·Healthcare
F Avoid
Current$66.79
Nov 8, 2026

Celcuity's FDA-approved REVTORPYK offers substantial oncology commercialization and indication-expansion potential, but unproven sales execution, persistent cash burn and shareholder dilution create significant investment risk.

Score
42
Arcus Biosciences, Inc.
RCUS·Healthcare
F Avoid
Current$18.28
Nov 7, 2026

Arcus Biosciences could establish casdatifan as a differentiated kidney cancer therapy, but persistent cash losses, shareholder dilution, and uncertain Phase 3 outcomes create substantial investment risk.

Score
42
Icahn Enterprises L.P.
IEP·Energy
F Avoid
Current$5.13
Nov 6, 2026

Icahn Enterprises offers exposure to valuable refining and investment assets with potential recovery catalysts, but persistent hedging losses, substantial unit dilution and parent-level leverage threaten sustainable per-unit returns.

Score
42
Viking Therapeutics, Inc.
VKTX·Healthcare
F Avoid
Current$27.28
Oct 31, 2026

Viking Therapeutics could establish a valuable obesity-drug franchise through injectable and oral VK2735, but its lack of revenue, substantial cash burn, and dependence on successful Phase 3 trials create significant investment risk.

Score
42
Bitmine Immersion Technologies, Inc.
BMNR·Financials
F Avoid
Current$22.40
Oct 25, 2026

Bitmine offers large-scale Ethereum exposure and growing staking revenue, but extraordinary dilution, weak cash generation, and cryptocurrency volatility threaten durable value creation for common shareholders.

Score
42